Gyros Protein Technologies

Microfluidic, nanoliter-scale immunoassays for rapid SARS-CoV-2 antibody analysis in serology testing, and vaccine and biotherapeutics development

Recorded Webinar from July 28, 2020

The unprecedented vaccine and therapeutic development efforts in response to the COVID-19 pandemic has created an urgent need for rapid, accurate, and sensitive assays to measure antibody responses to the SARS-CoV-2 virus. To meet this need, a microfluidic, nanoliter-scale immunoassay for qualitative detection of total antibodies generated against the spike protein (RBD) of SARS-CoV-2 in human serum samples has been developed using Gyrolab® immunoassay platform. The assay shows specificity towards SARS-CoV-2 antibodies in serum samples, and a broad range of approximately 40 to 200,000 ng/mL. With an assay completion time of one hour for 112 data points, high-throughput analysis is possible for serology tests and for immunoassays during vaccine or antibody therapeutic development.


Rob Durham, Ph.D.
Director of Service and Scientific Support
Gyros Protein Technologies

If you have problems viewing the webinar, please contact